Direct assessment of hereditary hemochromatosis in preimplantation genetic testing
In this study, we demonstrated the feasibility of using the PCR-RFLP approach to PGT. Specifically, we validated the assay for the HFE C282Y variant, the primary cause of type 1 hemochromatosis. The assay was tested on genomic DNA and DNA resulting from whole-genome amplification, achieving >99% accuracy, sensitivity, precision, and specificity. These results also suggest the possibility for extending the PCR-RFLP approach to cover a broader range of conditions, such as spinal muscular atrophy, to benefit more patients currently ineligible for testing at PGT laboratories.
Authors
- M. Katz (ORCID: https://orcid.org/0009-0008-2549-6387)
- N. J. Schuch
- Shenglai Li (ORCID: https://orcid.org/0000-0002-1227-4338)
- Noor Siddiqui
- Qinnan Zhang (ORCID: https://orcid.org/0000-0002-4608-4006)
- Yuntao Xia (ORCID: https://orcid.org/0000-0002-3011-5859)
- Benjamin Podgursky (ORCID: https://orcid.org/0009-0000-7072-4272)
- Funda Suer (ORCID: https://orcid.org/0000-0002-7790-6332)
Institutions
- Orchid Pharma (India) (IN)
- Durham County Department of Public Health (US)
- Genomic Health (United States) (US)
Publication Details
- Journal
- F&S Science
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1016/j.xfss.2024.12.003
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00